0 item(s)
View cart
You have no items in your shopping cart.
13
Apr
Eliminating False Positives: Achieving 96.83% Specificity in Oncology Diagnostics
Reducing background interference and enabling high-confidence clinical detection.
In clinical oncology diagnostics, specificity is critical. False positives can lead to severe misdiagnosis and inappropriate treatment decisions. Biofargo Leadonano™ Streptavidin magnetic beads are engineered to minimize non-specific binding and deliver high-fidelity diagnostic results.
Clinical Validation Using Real Patient Samples
To rigorously assess performance, Biofargo Leadonano™ 2.8 μm Streptavidin magnetic beads were validated using authentic clinical serum samples rather than artificial systems.
The study included breast cancer patients diagnosed with simple carcinoma, invasive ductal carcinoma, and adenocarcinoma, alongside healthy control samples.
Performance was benchmarked directly against leading imported 2.8 μm magnetic beads under identical assay conditions.
Key Performance Outcome
The results demonstrated that Biofargo Leadonano™ beads significantly improve assay specificity, achieving over 96.83%.
- Substantial reduction in non-specific binding
- Cleaner background signals across clinical samples
- Reliable differentiation between true positives and negatives
- Performance equivalent to or exceeding imported gold standards
This ensures that detected signals reflect true biomarker interactions, enabling accurate clinical interpretation.
Why It Matters
High specificity is essential for clinical diagnostics, particularly in oncology where diagnostic accuracy directly impacts treatment decisions.
By integrating Biofargo Leadonano™ magnetic beads, laboratories and IVD developers can:
- Reduce false-positive rates
- Improve diagnostic confidence
- Enhance assay robustness in complex matrices
- Deliver clinically reliable results at scale
Available Products
Biofargo team
